Li, W., Chen, K., Xu, M., Xu, C., Li, D., Li, D., Guo, Q., Zhang, D., Qian, R., Chen, X., Lu, H., Hu, W. (2026). Chidamide combined with serplulimab and regorafenib or fruquintinib as third-line therapy for advanced colorectal cancer (C-ooperate/SCOG-C001): A single-arm, exploratory, multicenter, phase 2 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e15583